Unlike traditional anticoagulants, the more recently developed agents rivaroxaban,
dabigatran and apixaban target specific factors in the coagulation cascade to attenuate …

Although the direct oral anticoagulants (DOAC s) do not require routine laboratory
monitoring, there may be special situations in which measurement of drug levels is …

Dabigatran etexilate, rivaroxaban and apixaban (DOACs) are widely used and
measurement of their concentration is desirable in certain clinical situations. Target-specific …

There are no clear and consistent guidelines on how to utilize DOAC assays, and reports on
the use of DOAC levels in clinical practice is limited. The objective of this study was to …

Background: The Direct Oral Anticoagulants (DOACs) represent a new generation of
antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or …

Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for
prevention and treatment of thromboembolic diseases. Although routine monitoring will not …

Long-term oral anticoagulant (OAC) therapy is used for the treatment and prevention of
thrombosis and thromboembolism. As OAC use is so widespread, emergency physicians …

Background The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be
inferred from their observed plasma concentrations; however, the steady-state …

Diagnostic of global coagulation parameters is part of the daily clinical routine practice in
conservative as well in operative disciplines. The correct interpretation of in vitro test results …

Rivaroxaban and dabigatran are new oral anticoagulants (NOACs) that inhibit directly factor
Xa and thrombin, respectively. These NOACs effectively prevent thromboembolic …